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Down’s syndrome (DS) is characterized by mental retardation and development of Alzheimer’s disease (AD). Oxidative stress and
mitochondrial dysfunction are both related to neurodegeneration in DS. Several genes in chromosome 21 have been linked to neuronal
death, including the transcription factor ets-2. Cortical cultures derived from normal and DS fetal brains were used to study the role of
ets-2 in DS neuronal degeneration. ets-2 was expressed in normal human cortical neurons (HCNs) and was markedly upregulated by
oxidative stress. When overexpressed in normal HCNs, ets-2 induced a stereotyped sequence of apoptotic changes leading to neuronal
death.DSHCNsexhibit intracellular oxidative stress and increasedapoptosis after the firstweek in culture (Busciglio andYankner, 1995).
ets-2 levels were increased in DS HCNs, and, between 7 and 14 d in vitro, DS HCNs showed increased bax, cytoplasmic translocation of
cytochrome c and apoptosis inducing factor, and active caspases 3 and 7, consistent with activation of an apoptotic mitochondrial death
pathway. Degeneration of DS neurons was reduced by dominant-negative ets-2, suggesting that increased ets-2 expression promotes DS
neuronal apoptosis. In the human brain, ets-2 expression was found in neurons and astrocytes. Strong ets-2 immunoreactivity was
observed inDS/ADandsporadicADbrainsassociatedwithdegenerativemarkers suchasbax, intracellularA, andhyperphosphorylated
tau. Thus, in DS/AD and sporadic AD brains, converging pathological mechanisms leading to chronic oxidative stress and ets-2 upregu-
lation in susceptible neurons may result in increased vulnerability by promoting the activation of a mitochondrial-dependent proapop-
totic pathway of cell death.
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Introduction
Down’s syndrome (DS) or trisomy 21 is the most common auto-
somal aneuploidy that survives birth and the singlemost frequent
genetic cause of mental retardation. The neuropathology of DS is
complex and includes development of Alzheimer’s disease (AD)
by middle age (Coyle et al., 1986; Mann, 1988; Lott and Head,
2001). Altered free radical metabolism and impaired mitochon-
drial function are linked to neuronal degeneration of DS cortical
neurons in culture (Busciglio and Yankner, 1995; Busciglio et al.,
2002) and may be associated with both mental retardation and
AD pathology in DS patients. Overexpression of several genes
localized in chromosome 21 has been linked to neuronal death,
including amyloid  precursor protein (APP) (Busciglio et al.,
2002), Cu/Zn superoxide dismutase (SOD1) (Bar-Peled et al.,
1996; de Haan et al., 1996), and the transcription factor ets-2
(Wolvetang et al., 2003a). The ets family of transcription factors
is involved in multiple cellular processes, including differentia-
tion, maturation, and activation of signaling cascades (Macleod
et al., 1992; Wasylyk et al., 1993). In mammals, ets-2 is ubiqui-
tously expressed in various tissues during development and
adulthood (Bhat et al., 1987; Kola et al., 1993). Previous work on
a transgenic mouse model indicates that overexpression of ets-2
may recapitulate several features of DS pathology (Sumarsono et
al., 1996). Moreover, increased levels of ets-2 predispose to apo-
ptosis via a p53-dependent pathway (Wolvetang et al., 2003a),
and neuronal cultures derived from ets-2 transgenic mice exhibit
caspase activation (Wolvetang et al., 2003b). Both ets-2 and p53
expression are upregulated in DS fibroblast and cortical cultures
(Wolvetang et al., 2003a), suggesting that DS cells may be more
sensitive to proapoptotic stimuli than normal (NL) cells. Induc-
tion of apoptosis by p53 is usually achieved through a mitochon-
drial death pathway, which includes upregulation and activation
of several proapoptotic factors such as bax, Apaf-1, andPERP and
transcriptional inhibition of anti-apoptotic components includ-
ing Bcl-2 and IAPs (Johnstone et al., 2002). Because mitochon-
drial dysfunction and increased apoptosis may be relevant fea-
tures of DS neuropathology, we investigated the involvement of
ets-2 and the mitochondrial apoptotic pathway in DS neuronal
death. The results indicate that ets-2 promotes degeneration of
DS cortical neurons in culture by activation of a mitochondrial
death pathway. In DS/AD and sporadic AD brains, strong ets-2
expression was associated with bax, intracellular A, and hyper-
phosphorylated tau, suggesting that upregulation of ets-2 in sus-
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ceptible neurons may result in increased
neuronal vulnerability and degeneration.
Materials andMethods
Neuronal cultures. Normal and DS human cor-
tical neuron (HCN) cultures were prepared as
described previously (Busciglio et al., 2002;
Pelsman et al., 2003). The protocol for tissue
procurement complied with federal and insti-
tutional guidelines. Briefly, cells were plated on
culture dishes or glass coverslips at a density of
100,000 cells/cm2 and maintained in serum-
free DMEM supplemented with N2 and B27
supplements (Invitrogen, Grand Island, NY).
Antibodies. The following antibodies were
used: rabbit anti-ets-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA); mouse monoclonal anti-
A42, which specifically recognize the C termi-
nus of Ax-42 (Busciglio et al., 2002); mouse
anti--tubulin isotype III (Sigma, St. Louis,
MO); mouse anti-p53 (Sigma); mouse mono-
clonal anti-cytochrome c (BD Transduction
Laboratories, San Diego, CA); mouse anti-
phosphorylated tau (PHF-1); mouse anti-bax
(Santa Cruz Biotechnology), rabbit anti-AIF
(Chemicon, Temecula, CA); rabbit anti-
activated caspase 3 (CM1; PharMingen, SanDi-
ego, CA); rabbit anti-activated caspase 7 (Cell
Signaling Technology, Beverly, MA); mouse
anti-neurofilaments (Sigma); and mouse anti-
GFAP (Sigma).
Western blot analysis. For Western blot anal-
ysis, cultures were washed with PBS and har-
vested in radioimmunoprecipitation assay
buffer plus protease inhibitors (Complete;
Roche Bioscience, Palo Alto, CA) at 4°C. Ly-
sates were centrifuged at 100,000  g for 30
min. Protein concentration was determined us-
ing a commercial kit (Bio-Rad, Hercules, CA). Samples were electro-
transferred to polyvinylidene difluoride membranes (PVDF) (Bio-Rad),
blocked, and incubated overnight at 4°C with primary antibody and
developed by enhanced chemiluminescence (Amersham Biosciences,
Piscataway, NJ). In all experiments, the tubulin level was used as control
for protein loading (anti-tubulin; clone DM1A; Sigma). ets-2, p53, and
bax antibody specificity were confirmed by preabsorption of the primary
antibodies with synthetic peptide, which abolished immunoreactivity.
Quantitative Western blot analysis was performed as described previ-
ously (Pigino et al., 2001, 2003).
Immunofluorescence and image analysis. Cultured cells were fixed for
30 min at 37°C in 4% paraformaldehyde and 0.12 M sucrose in PBS and
permeabilized with 0.2% Triton X-100 in PBS. Double immunofluores-
cence was performed as described previously using Alexa-conjugated
secondary antibodies (Molecular Probes, Eugene, OR) (Busciglio et al.,
2002).
Brain tissue samples for immunohistology were obtained from the
Institute for Brain Aging and Dementia Tissue Repositories at the Uni-
versity of California, Irvine; the University of Miami Brain and Tissue
Bank for Developmental Disorders through National Institute of Child
Health and Human Development contract NO1-HD-8-3284; and the
Harvard Brain and Tissue Resource Center, McLean Hospital, and Mas-
sachusetts General Hospital. Brain tissue from the parietal cortex, ento-
rhinal cortex, and hippocampus of five neuropathologically confirmed
DS/AD cases and six age-matched controls were included in this study.
Mean age at the time of death was not significantly different between
DS/AD (mean, 53.40 7.20 SD) and controls (mean, 64.33 12.08 SD).
In addition, four different specimens of sporadic AD were analyzed
(mean age, 72.7  6.60 SD). Tissue sections were processed for immu-
nofluorescence as described previously (Head et al., 2002). Competition
with antigenic peptide, use of nonimmune IgG instead of primary anti-
body, or omission of primary antibody resulted in complete elimination
of specific labeling. An Axiovert 200 inverted microscope (Zeiss, Jena,
Germany) was used for specimen examination and imaging. Fluorescent
images were captured with a digital camera (Zeiss) and processed using
AxioVision (Zeiss). Fluorescent intensity measurements in tissue sec-
tions processed in parallel were performedusingNIH Image software. To
quantify the frequency of colocalization of fluorescent signals, at least 20
fields per section of each individual case were captured at a final magni-
fication of 630 and analyzed using AxioVision software. For some ex-
periments, z-stacks of images were captured, processed, and rendered
using the Apotome imaging system (Zeiss).
Treatment with H2O2. Treatment with H2O2 (Sigma) was performed
as described previously (Pelsman et al., 2003). Briefly, a fresh stock of 1
mM H2O2 was prepared in DMEM before each experiment. At day 7 in
culture, H2O2 was added to the culture medium of HCN at 50 M final
concentration. After 1 h, the cultures were washed with fresh medium
and maintained for an additional 2 and 4 h before harvesting. After this
period, the cultures were processed for analysis.
Transfection. Full-length ets-2 (Wolvetang et al., 2003a) and a
dominant-negative ets-2 construct (DN) were cloned into pcDNA3 (In-
vitrogen). The DN expression vector contains the human ets-2 sequence
encoding amino acids 280–476. This construct lacks the transactivation
domain but conserves the DNA binding domain, competing with the
wild-type protein for the same recognition sites (Chumakov et al., 1993).
Both constructs were confirmed by sequencing. Green fluorescent pro-
tein (GFP), p53 wild-type, and p53 dominant-negative (m135) expres-
sion vectors were obtained from Clontech (Palo Alto, CA). For most
experiments, HCNs were transfected at 7d in culture. Cultures were in-
cubated for 4 h with Lipofectamine (Invitrogen) andDNA (1g of DNA
plus 1 l of Lipofectamine per 500 l of medium). Cultures were co-
transfected with different vectors (GFP/ets-2, GFP/DN, ets-2/DN, ets-2/
Figure 1. Ets-2 expression is elevated in DS cortical neurons and can be upregulated by oxidative stress in normal neurons. A,
B, ets-2 immunofluorescence (anti-ets-2, 1:500) in NL and DS cortical neurons fixed at 5 DIV. Scale bar, 20m. C, Western blot
analysis shows a gradual increase in ets-2 levels during development of HCN in culture. DIV, Days in vitro. D, ets-2 expression in
cultures generated from two different DS (17 and 18 weeks of gestational age) and two normal (17 and 18 weeks of gestational
age) specimens, respectively. Expression of ets-2 in fetal human cortex (Ctx) is shown. ets-2-transfected COS cells (Cos)were used
as positive control for antibody specificity. Specific labeling was completely abolished by preabsorption of the primary antibody
with antigenic peptide (preab). The same samples (normal and DS) probed with an antibody against -tubulin showed no
significant differences in -tubulin content. Normal and DS cultures at 3 DIV were homogenized, subjected to SDS-PAGE, and
blotted onto a PVDFmembrane. The blots were revealed with anti-ets-2 (1:1000) and amonoclonal against neuronal-tubulin
class III (1:2000). A total of 20g of proteinwas loaded per lane. E, The histogram shows ets-2 levels at 3 DIV in NL (standardized
as 100%) and DS cultures. Four DS and four normal specimens were included in the analysis. Quantitative Western blots were
performed as described inMaterials andMethods. Values are expressed asmean SEM by unpaired Student’s t test. *p 0.02.
F, Induction of ets-2 expression in normal HCN by treatmentwith H2O2. HCNswere treated at 7 DIVwith 50MH2O2 for 1 h. Then,
H2O2 was removed, and the cultures were incubated for an additional 0, 2, and 4 h, respectively. No significant impairment of
neuronal viability was observed. Treatment with H2O2 did not change tubulin levels. A total of 20g of protein was loaded per
lane.
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m135, and p53/m135). The efficiency of transfectionwas20–30%, and
the efficiency of cotransfection was previously established as 95%
(Pigino et al., 2001). Cultures were transfected in 24-well plates in qua-
druplicate wells, fixed, and analyzed 24 h after transfection. No changes
in cell viability were observed in neurons transfected with empty vector
or GFP expression vector.
Viability assay. Neuronal viability was evaluated using a propidium
iodide (PI) (Molecular Probes) exclusion assay as described previously
(Busciglio and Yankner, 1995; Busciglio et al., 2002; Grace et al., 2002).
The number of viable neurons (defined as neurons displaying GFP-
positive cell bodies and propidium-negative nuclei) in ets-2-, DN-, p53-,
or m135-transfected neurons was expressed as a percentage of the num-
ber of viable neurons transfected with GFP alone in control cultures.
More than 200 cells were analyzed per experimental condition in each
individual experiment.
Statistical analysis. All experiments were repeated at least three times
using different brain specimens or cultures derived from at least three
different embryos. Each individual experiment was performed in qua-
druplicate and scored by a blinded observer. Data were analyzed by Stu-
dent’s t test or ANOVA followed by Student–
Newman–Keuls post hoc test. Data were
expressed asmean SEM, and significance was
assessed at p 0.05.
Results
Analysis of ets-2 expression in normal
and DS HCN
The first set of experiments was directed to
analyze and characterize the pattern of ex-
pression of ets-2 in HCNs. Immunocyto-
chemical analysis showed expression of
ets-2 in HCN cultures derived from both
NL and DS fetal brains (Fig. 1A,B). Ex-
pression of ets-2 was also observed in as-
trocytes (data not shown). Western blot
analysis of NL neuronal cultures revealed a
progressive increase in ets-2 protein levels
during neuronal development in vitro
(Fig. 1C), suggesting that ets-2 activity
may play a role in neuronal development
and/or maturation. Consistent with this
result, significant ets-2 expression was de-
tected in fetal human cortex (Fig. 1D).
Quantitative analysis revealed that ets-2
level in DSHCNswas increasedmore than
twofold compared with normal HCN
(225  37% SEM), which is significantly
higher than predicted by gene dosage (Fig.
1D,E). Previous experiments have shown
that ets-2 expression is upregulated by ox-
idative stress in fibroblast cell lines (Sanij
et al., 2001). Because DS cortical neurons
exhibit increased levels of reactive oxygen
species in culture (Busciglio and Yankner,
1995), we explored whether ets-2 expres-
sion could be modulated by oxidative
stress in human neurons. HCNs were
treated with H2O2 (50 M) for 1 h. This
concentration of H2O2 was chosen be-
cause it does not affect neuronal viability
during the first 4–6 h of treatment. After
24 h, it induces moderate cell death, simi-
lar to what is observed inDSHCNs under-
going degeneration in culture (Pelsman et
al., 2003). Hydrogen peroxide treatment
induced a significant increase in ets-2,
which was evident after 2 and 4 h (Fig. 1F). Thus, oxidative stress
upregulates ets-2 expression in cultured HCN and, together with
gene dosage, may contribute to elevated ets-2 levels in DS
neurons.
Overexpression of ets-2 induces cytochrome c cytoplasmic
translocation and apoptotic features in HCNs
Previous results using an ets-2 transgenicmousemodel show that
ets-2 overexpression induces apoptosis of thymus, spleen, and
brain cells (Wolvetang et al., 2003a,b). To establish the effect of
ets-2 increased expression in HCNs, cultures were cotransfected
with ets-2 and GFP expression vectors at 7 d. During the follow-
ing 24 h after transfection, ets-2-expressing neurons progressed
through a stereotyped sequence of degenerative changes that cor-
related with apoptotic features. Time-lapse microscopy revealed
that morphological changes included thinning and beading of
Figure 2. Overexpression of ets-2 in HCNs induces a sequence of degenerative changes leading to neuronal death. Rows I–IV
illustrate the sequence of alterations observed in HCNs overexpressing ets-2. Columns show differential interference contrast
images (DIC), GFP fluorescence (green; GFP/ets-2), cytochrome c immunofluorescence (1:500; red; cyt-C), Hoechst DNA staining
(blue, hoechst), and merged fluorescent channels (merge). Six hours after transfection, most transfected neurons exhibited
normal morphology, intact neuritic processes (row I; DIC and GFPets-2; arrows and arrowheads), intense fluorescence of
mitochondrial cytochrome c in cell bodies and neurites (row I; cyt-C; arrowhead and arrow), and normal nuclearmorphology (row
I; Hoechst; arrow). Between 12 and 24 h after transfection, initial morphological alterations, including thinning and beading of
neurites (row II; DIC and GFPets-2; arrowheads), were accompanied by loss of discrete immunofluorescence and localization of
cytochrome c in mitochondria (row II; cyt-C; arrow). At this stage, neurons still exhibited normal nuclear morphology (row II;
hoechst; arrow). Subsequent changes included shrinkage of cell bodies and accentuated neuritic beading (row III; DIC and GFP/
ets-2; arrows and arrowheads) and nuclear condensation (row III; hoechst; arrow). The last stage was characterized by neuritic
fragmentation (row IV; DIC and GFP/ets-2; arrowheads) and further nuclear condensation (row IV; Hoechst; arrows). Transfection
of GFP alone did not affect neuronal morphology or viability. Scale bar, 20m.
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neuronal processes, shrinkage of cell bodies, and neuritic frag-
mentation. Between 6 and 12 h after transfection, most trans-
fected neurons exhibited normal morphology (Fig. 2, row I).
After 12 h, morphological changes started to become evident and
correlatedwith the sequential appearance of apoptotic features as
follows: (1) the initial alterations in neuritic processes were ac-
companied by a loss of discrete immunofluorescence and local-
ization of cytochrome c in mitochondria (Fig. 2, row II); (2)
shrinkage of cell bodies was associatedwith nuclear condensation
(Fig. 2, row III); and (3) the last stage was characterized by neu-
ritic fragmentation (Fig. 2, row IV) and loss of membrane integ-
rity evidenced by positive PI staining (Fig. 3A). These alterations
did not occur synchronically in transfected neurons, probably
because of the heterogeneous nature of the neuronal population
in cortical cultures. Consequently, at any given time between 12
and 24 h after transfection, neurons at different stages of neuro-
degeneration were observed. Quantification of cell viability using
PI staining revealed that less than half of ets-2-transfected neu-
rons remained viable after 24 h (46  2.7%) (Fig. 3C). In con-
trast, 24 h after transfection, control neurons expressing GFP did
not show degenerative features or reduced viability (Fig. 3C). To
confirm the involvement of ets-2 overexpression in neuronal cell
death, we generated a dominant-negative ets-2 expression vector
lacking the transactivation domain, which has been shown to
abrogate ets-2 activity (DN) (Chumakov et al., 1993). Coexpres-
sion of DN with ets-2 prevented the appearance of degenerative
features and significantly increased neuronal viability to 65 
4.5% (Fig. 3B,C). Hence, ets-2 overexpression in HCN induces
the progressive appearance of apoptotic features, which can be
prevented by coexpression of DN.
Previous work indicates that ets-2mediates cell death through
a p53-dependent pathway (Wolvetang et al., 2003b). A palin-
dromic sequence in the promoter of the human p53 gene con-
tains two ets-binding elements, to which ets-2 binds with high
affinity to activate p53 transcription (Venanzoni et al., 1996; Se-
mentchenko and Watson, 2000). Consistent with these observa-
tions, we found a significant increase in p53 protein level in cul-
tures transfected with ets-2 but not with GFP (Fig. 3D). The role
of p53 in ets-2-mediated death in HCNs was further assessed
using a p53 dominant-negative expression vector (m135) (Schef-
fner et al., 1992; Vogelstein and Kinzler, 1992). Cotransfection
withm135 reduced significantly both ets-2-induced (Fig. 3C, ets-
2/m135) and p53-induced (Fig. 3C, p53/m135) neuronal cell
death. These experiments indicate that ets-2 overexpression in-
duces a p53-dependent mitochondrial apoptotic pathway in
HCNs.
Amitochondrial death pathway is involved in the
degeneration of DS cortical neurons
We have shown previously that DS HCNs exhibit intracellular
accumulation of reactive oxygen species, lipid peroxydation, de-
generative morphological changes including neuritic retraction
and fragmentation, shrinkage of cell bodies, chromatin conden-
sations and positive terminal deoxynucleotidyl transferase-
mediated biotinylated UTP nick end labeling staining (Busciglio
and Yankner, 1995; Pelsman et al., 2003). During the second
week in culture, DS neurons undergo progressive degeneration,
and by day 14, only 41 3% of the neurons originally present at
day 7 are viable (Busciglio and Yankner, 1995). To further inves-
tigate themolecularmechanisms involved inDS neuronal degen-
eration and their potential relationship with ets-2 overexpres-
sion, we analyzed apoptotic effectors of the mitochondrial death
pathway downstream of p53 (Johnstone et al., 2002; Danial and
Korsmeyer, 2004). p53 can induce apoptosis by transcription-
dependent or independent mechanisms. Both pathways involve
activation of the proapoptotic factor bax and increased perme-
ability of the inner mitochondrial membrane mediated by the
mitochondrial permeability transition pore, leading to mito-
chondrial release of cytochrome c and apoptosis inducing factor
(AIF), and activation of caspases (Mihara et al., 2003; Chipuk et
al., 2004). The following experiments were performed at 8 DIV,
when DS neurons had already started to exhibit the progression
of degenerative features referred above. Quantitative Western
blot analysis showed that the level of bax was increased almost
twofold inDS comparedwith normalHCNhomogenates (198
28%) (Fig. 4A). Immunofluorescence image analysis revealed
that both cytochrome c and AIF showed diffuse cytoplasmic lo-
calization in cell bodies and processes of 11 6% of DS neurons
devoid of obvious degenerative morphology (Fig. 4B), reminis-
cent of the initial stage of degeneration of normal HCN overex-
pressing ets-2 (Fig. 2, row II). In contrast, discrete labeling and
restricted mitochondrial localization of cytochrome c and AIF
was observed in cell bodies and processes of normal HCN (Fig.
4B). The presence of activated caspase 3 was detected in 9 4%
of DS neurons, most of them exhibiting shrinkage of cell bodies
and neuritic fragmentation (Fig. 4C), which resembled the de-
Figure 3. Dominant-negative ets-2 reduces ets-2-induced neuronal degeneration. A, B,
GFP/ets-2 transfectedHCNs exhibit neuritic fragmentation, loss of cellmembrane integrity, and
chromatin condensation evidenced by positive PI staining (A, arrow). Coexpression of ets-2 and
a dominant-negative ets-2 prevented cell death in HCNs (B). Neurons were visualized by GFP
fluorescence. Scale bar, 20m. C, P53mediates ets-2-induced neuronal death in HCNs. Viabil-
ity assessment of HCN cultures transfected with the indicated vectors. Overexpression of ets-2
and p53 significantly reduced neuronal viability. Cotransfection with dominant-negative ets-2
or p53 (m135) vectors partially prevented ets-2- and p53-mediated neuronal cell death (est-2/
DN; ets-2/m135; p53/m135). Primary cortical cultures were transfected at 7 DIV and fixed 24 h
later. Before fixation, nonviable cellswere labeledwith propidium iodide. After fixation, immu-
nofluorescence with anti-ets-2 (1:500) or anti-p53 (1:200) antibodies was performed, and the
number of both transfected viable neurons and transfected propidium-positive neurons was
scored. The histogram shows the relative number of viable transfected neurons in each condi-
tion. All experiments were performed in quadruplicate cultures and replicated at least three
times. Values are the mean SE; n 300 transfected neurons per experimental condition.
*p 0.05 relative to GFP transfected cultures (ctrl; 100%) using Student’s t test; asterisks
indicate a significant difference from ets-2-transfected cultures (**p 0.05).D, ets-2 overex-
pressionupregulates p53.Westernblot analysis of cultures transfectedwithGFP, ets-2, andp53
expression vectors is shown. The blotwas developedwith anti-p53 (1:250). Note the increase in
p53 level in ets-2-transfected cells comparedwithGFP transfected cells. A total of 20gof total
protein homogenate was loaded per lane.
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generative morphology of normal HCNs overexpressing ets-2
(Fig. 2, row III). A similar number of DS HCNs exhibiting acti-
vated caspase 7 was detected by immunofluorescence inDSHCN
(data not shown). Thus, degenerating DS neurons exhibit fea-
tures associated with the activation of a mitochondrial death
pathway: increased levels of bax and cytoplasmic translocation of
cytochrome c and AIF were observed in DS neurons that did not
exhibit degenerative morphological changes, whereas the pres-
ence of active caspases was associated with the appearance of
degenerative morphological features.
Dominant-negative ets-2 expression increases DS
neuronal survival
To establish a potential role for ets-2 increased expression in DS
neuronal death, we reduced ets-2 activity in DS neurons by ex-
pressing ets-2 dominant-negative (DN). Transfection ofGFP and
DN were performed at 7 d in culture, and after 24 h, the cultures
were processed and analyzed. Fluorescent microscopy revealed
that degenerating DS neurons transfected
with GFP exhibited similar changes as de-
scribed for degenerating, nontransfected
DS neurons, including neuritic beading
and fragmentation, cell body shrinkage,
and nuclear condensation (Fig. 5A) (Bus-
ciglio and Yankner, 1995). In contrast, DS
neurons coexpressing DN/GFP exhibited
normal morphology and lack of degenera-
tive features (Fig. 5B). Quantification of
neuronal cell death using PI showed a
marked reduction in the number of PI-
positive DS neurons expressing DN/GFP
(46 4%) compared with DS neurons ex-
pressing GFP alone (100 8%) (Fig. 5C).
This result suggests that overexpression of
ets-2 may contribute to DS neuronal de-
generation and that inhibition of ets-2 ac-
tivity increases DS neuronal survival in
culture.
ets-2 expression in DS and AD brains is
associated with
neurodegenerative features
Immunofluorescence analysis of ets-2 in
normal adult brains revealed that ets-2 is
expressed in neurons and astrocytes (Fig.
6). The identity of ets-2-positive neurons
was confirmed by double labeling with
anti-neurofilament antibody (Fig. 6A,B),
whereas ets-2-positive astrocytes were
identified by double labeling with anti-
GFAP (Fig. 6C,D). A low level of ets-2 ex-
pression in the cytoplasm of both neurons
and astrocytes was observed throughout
the cortex and hippocampal formation
(Fig. 6E). Analysis of DS brains gave simi-
lar results (Fig. 6F), and image analysis re-
vealed no significant differences in the in-
tensity of ets-2 immunofluorescence
between normal and DS brain sections
(data not shown), suggesting a lack of con-
stitutive upregulation of ets-2 in adult DS
brains attributable to gene dosage.
To explore the association between
ets-2 and neuronal death in situ, we analyzed the relationship
between ets-2 expression, markers of apoptosis, and AD neuro-
pathology in both DS/AD and sporadic AD brains. In DS/AD
brains, we found increased ets-2 immunoreactivity associated
with bothmarkers of apoptosis and AD classic lesions. For exam-
ple, image analysis indicated that high ets-2 expression was ob-
served in 86  11% of neurons showing bax immunofluores-
cence (Fig. 7A), suggesting a close association between ets-2
upregulation and apoptosis in DS brains. A number of studies
have characterized the presence of intracellular A in the brain of
DS and AD patients as well as transgenic mouse models (Gouras
et al., 2000; Busciglio et al., 2002; Oddo et al., 2003; Takahashi et
al., 2004). Strong ets-2 immunoreactivity was found in 62 3%
of cortical and hippocampal neurons exhibiting intracellular A
(Fig. 7B). We also found an association between ets-2 and tau
cytoskeletal pathology. Most neurons displaying hyperphospho-
rylated tau also showed high levels of ets-2 immunofluorescence
(69 7%) (Fig. 7C), which was evident in cells displaying differ-
Figure 4. Evidence for the activation of a mitochondrial death pathway in DS neurons. A, Left, The histogram shows the
quantification of bax expression in NL (standardized as 100%) and DS cortical cultures at 8 DIV. Four normal and four DS indepen-
dent cultures were used for the analysis. Values are expressed as mean SEM by unpaired Student’s t test. *p 0.05. Right,
RepresentativeWestern blot showing bax expression inNL andDSneuronal cultures (anti-bax, 1:500).B, Differential interference
contrast (DIC) imaging shows neurons with intact morphology in NL and DS cultures at 8 DIV. Double immunofluorescence of
normal andDSneuronswith anti-cytochrome c (1:500; cyt C) and anti-AIF (1:400; AIF) antibodies showmitochondrial localization
of cytochrome c and AIF in cell bodies (NL; arrowheads) and processes (NL; arrows) of normal neurons. In contrast, DS neurons
exhibit diffuse cytochrome c and AIF staining in both cell bodies (DS; arrowheads) and neuronal processes (DS; arrows). Bottom
panels are highermagnifications of framed areas. Scale bar, 20m. C, Immunofluorescence shows positive immunoreactivity for
active caspase 3 (1:1000) in DS neuronal cell bodies (red fluorescence; arrows). Normal neurons showed negative labeling for
active caspase 3. Neurons were double labeled with anti-tubulin class III (1:2000; blue fluorescence). Scale bar, 20m.
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ent degrees of tau cytopathology, from pretangle stages (Fig. 7C,
large arrow) to mature tangle-bearing neurons (Fig. 7C, small
arrow). However, ets-2 was not detected to be associated with
extracellular tangles (data not shown). Upregulation of ets-2 did
not appear to be secondary to intracellular A or tau hyperphos-
phorylation in affected neurons, because significant ets-2 expres-
sion was also observed in adjacent neurons lacking intracellular
labeling for A or hyperphosphorylated tau (Fig. 7C, arrow-
head). Finally, high ets-2 expression was frequently found in as-
trocytes surrounding senile plaques (52  16%) (Fig. 7D), im-
plying a potential association between upregulation of ets-2 and
astrocyte activation in plaque-rich cortical and hippocampal re-
gions. Analysis of sporadic AD brains revealed similar results
(Fig. 8). Strong ets-2 expression was present in cells localized in
pathology-rich areas (Fig. 8A), particularly associated with tau
cytopathology (Fig. 8B). Image analysis indicated that the fre-
quency of colocalization of ets-2 with hyperphosphorylated tau
in sporadic AD brain sections was 62 13%. These results indi-
cate that, in DS/AD and sporadic AD brains, strong ets-2 expres-
sion is observed in regions of abundant neuropathology, where it
is often associated with markers of apoptosis and AD lesions.
Discussion
Neuronal degeneration and development of AD are major fea-
tures associated with DS. A major challenge is to characterize the
genes located in chromosome 21, which contribute to loss of
neuronal function and viability. Here, we show that ets-2 is ex-
pressed during normal HCN development in culture and that its
expression is increasedmore than twofold inDS cortical neurons.
However, no significant differences in general intensity, fre-
quency, and localization of ets-2 expression were found between
normal and DS brains. Thus, intracellular pro-oxidant condi-
tions in DS neurons in culture, leading to increased generation of
reactive oxygen species (Busciglio and Yankner, 1995), may ac-
count for the significant increase in ets-2 expression. This possi-
bility is supported by a marked upregulation of ets-2 in normal
HCN cultures treated with hydrogen peroxide. Overexpression
of ets-2 in normal HCN led to a progressive pattern of neuronal
degeneration, whichwas significantly reduced by coexpression of
a dominant-negative form of ets-2. Similarly, DS HCN express-
ing dominant-negative ets-2 showed normal morphology and
increased survival, implying the involvement of ets-2 in DS neu-
ronal degeneration.
The role of p53 in the death pathway activated by ets-2 has
been characterized previously in ets-2 transgenic models (Wol-
vetang et al., 2003a,b). In addition, increased p53 expression has
been reported in DS fibroblasts, cortical cultures, and DS brains
(Seidl et al., 1999; Wolvetang et al., 2003b). The involvement of
p53 in ets-2-induced degeneration is further supported by exper-
iments showing increased survival of normal HCN cotransfected
with ets-2 and m135 (Fig. 3C) and increased survival of DS neu-
rons transfected withm135 (A. Pelsman and J. Busciglio, unpub-
lished result).
DS cortical neurons undergo increased apoptosis during the
Figure 5. Expression of dominant-negative ets-2 increases DS neuronal survival. A, B, At 8
DIV, DS cortical neurons expressing GFP undergo degenerative changes similar to nontrans-
fected DS neurons, including shrinkage of cell bodies, neuritic beading, and fragmentation (A,
arrows). In contrast, DS cortical neurons cotransfected with ets-2 dominant-negative and GFP
(GFP/DN) exhibit normalmorphology and viability (B). Neuronswere visualized by GFP fluores-
cence. Scale bar, 20 m. C, Quantification of PI-positive DS neurons transfected with GFP or
GFP/DN. There is a significant reduction in the number of PI-positive DS neurons transfected
with GFP/DN comparedwith neurons transfectedwith GFP alone. Transfection of GFP alone did
not affectDSneuronalmorphologyor viability. Cultureswere transfectedat 7DIVand fixedafter
24 h. Values are the mean SE; n 300 transfected neurons per experimental condition.
*p 0.05 relative to GFP transfected cultures (100%) by Student’s t test.
Figure 6. Ets-2 expression in normal and DS brains. A–D, Double immunofluorescence re-
veals ets-2 expression (anti-ets-2, 1:100) in neurons (A, B) and astrocytes (C, D) in normal
entorhinal cortex. Neuronal identity was confirmed by positive anti-neurofilament staining
(1:200;A), and astrocyteswere labeledwith anti-GFAP (1:200; C). Cellular nuclei were counter-
stained with Hoechst (blue fluorescence). E, F, Lower magnification illustrates similar level of
ets-2 expression in cortex of NL and DS subjects. Images in A–D are optical sections (thickness,
0.375m) processed with the Apotome device (Zeiss). Scale bars: A–D, 10m; E, F, 20m.
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second week in culture (Busciglio and
Yankner, 1995). During this period, we
found alterations in downstream apopto-
tic effectors, including a marked increase
in bax protein levels, release of cytochrome
c and AIF from mitochondria to cytosol,
and activation of caspases 3 and 7. Simi-
larly, increased activated caspase 3 and ap-
optosis is observed in neuronal cultures
generated from ets-2 transgenic mice
(Wolvetang et al., 2003b). Collectively,
these results suggest a close association
among oxidative stress, increased expres-
sion of ets-2, and activation of amitochon-
drial death pathway in DS neurons. More-
over, the presence of a similar sequence of
morphological and molecular degenera-
tive features in normalHCNs overexpress-
ing ets-2 and in DS HCN further suggests
that ets-2 may play a role in DS neuronal
degeneration. In this regard, a number of
studies provide evidence of bax expres-
sion, caspase activation, and apoptosis in
fetal and adult DS brains (de la Monte,
1999; Sawa, 1999; Seidl et al., 1999;Head et
al., 2002; Su et al., 2002)
Distinct, albeit low levels of ets-2 ex-
pression were present in the adult brain in
neurons and astrocytes in the cortex and
hippocampus. A previous biochemical
study did not find major differences in
ets-2 protein levels between control and
DS brains (Engidawork et al., 2001). In
agreement with those results, we found
similar levels of ets-2 immunoreactivity
throughout cortical and hippocampal ar-
eas in both normal and DS brains. In contrast, higher ets-2 im-
munoreactivity was evident in cells associated with markers of
apoptosis and neurodegeneration in both DS/AD and sporadic
AD brains. For instance, strong ets-2 expression was found in
neurons exhibiting positive bax immunofluorescence aswell as in
neurons showing intracellular A accumulation or different
stages of tau cytopathology. Interestingly,marked ets-2 immuno-
reactivity was also observed in adjacent neurons devoid of the
above-mentioned pathological markers, suggesting that the in-
crease in ets-2 expression might precede their appearance. Both
A and tau cytopathology have been associated with pro-oxidant
intracellular conditions, raising the possibility that chronic oxi-
dative stress in DS/AD and sporadic AD brains upregulates ets-2
expression in susceptible neurons (Sayre et al., 2000; Busciglio et
al., 2002; Mandelkow et al., 2003). In this scenario, ets-2 in-
creased expression would result in enhanced neuronal vulnera-
bility and degeneration regardless of ets-2 gene dosage. However,
our results do not unequivocally rule out a subtle increase in ets-2
expression inDS brain as a result of gene dosage. Consequently, a
combinatorial or even synergistic effect of gene dosage and oxi-
dative stress may pose an additional challenge to neuronal sur-
vival in DS brains, consistent with an earlier onset of AD pathol-
ogy in DS subjects than in sporadic cases. Ongoing experiments
are directed to determine the expression level of ets-2 and its
association with markers of oxidative damage in DS, AD, and
other neurodegenerative conditions associated with increased
oxidative stress such as Parkinson’s and Huntington’s diseases.
Figure 8. Strong ets-2 immunoreactivity associated with degenerative markers in sporadic
ADbrains. Immunofluorescencewith anti-ets-2 illustrates strong ets-2 expression in cell bodies
located in the entorhinal cortex of a sporadic AD patient (arrows; A). Double immunofluores-
cence with anti-ets-2 (green) and PHF-1 (red) denotes marked ets-2 immunoreactivity in neu-
rons displaying different stages of tau cytopathology: mature tangle-bearing neuron (arrow)
and diffuse tangle-bearing neuron (arrowhead). In contrast, an extracellular tangle shows neg-
ative ets-2 immunoreactivity (small arrow). The image inB is a z-stack of optical sections 3m
thick. Scale bars, 20m.
Figure 7. Increased ets-2 expression is associated with apoptosis and degenerative markers in DS/AD brains. Double immu-
nofluorescence of DS/AD brains is shown. A, Anti-ets-2 (1:100; green fluorescence) and anti-bax (1:100; red fluorescence) show-
ing immunoreactivity for both antigens in the cytoplasmof a neuron in the entorhinal cortex.B, Anti-ets-2 (red fluorescence) and
monoclonal anti-A42 (1:50; green fluorescence) labeling in the cytoplasm of a neuron located in the hippocampal formation. C,
Anti-ets-2 (green fluorescence) and anti-hyperphosphorylated tau (1:1000; red fluorescence). Ets-2 immunoreactivity is present
in entorhinal neurons displaying different degrees of tau pathology: a mature tangle-bearing neuron (small arrow) and a diffuse
tangle-bearingneuron (large arrow). Significant ets-2 immunoreactivity is present in an adjacent neuronnegative for hyperphos-
phorylated tau (arrowhead). D, Ets-2 immunoreactivity in astrocytes (arrows; green fluorescence) surrounding a senile plaque
stained with anti-A (asterisk; red fluorescence). Images in A and B are optical sections (thickness, 0.375m). Images in C and
D are z-stacks of optical sections. Thickness of the stacks rendered in C and D are 3.75 and 1.12m, respectively. Images were
processed with the Apotome device (Zeiss). Scale bar, 20m.
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In DS, chronic mitochondrial dysfunction is associated with
APP overexpression and the presence of intracellular A (Bus-
ciglio et al., 2002), both of which can translocate tomitochondria
and aggravate the energy shortfall and oxidative stress (Anan-
datheerthavarada et al., 2003; Lustbader et al., 2004). In a similar
way, increased SOD1 activity in the mitochondrial intermem-
brane space may increase free radical generation and mitochon-
drial dysfunction (de Haan et al., 1996; Okado-Matsumoto and
Fridovich, 2001). Hence, several toxic mechanisms associated
with upregulation of specific genes localized in chromosome 21
(e.g., ets-2, APP, and SOD1) may converge in DS mitochondria,
leading to chronic metabolic impairment, oxidative stress, and
neuronal degeneration (Busciglio et al., 1998). In this regard,
studies on early AD patients and patients at risk of AD show
hypometabolism in posterior cingulate and temporal cortex as
indicators of the disease process, which strongly suggest energy
deficits associated with disease progression. In contrast, nonde-
mented DS subjects exhibit inferior temporal/entorhinal cortex
hypermetabolism (Minoshima et al., 1997; Silverman et al., 2001;
Alexander et al., 2002). This increase in metabolic rate can be
interpreted as a compensatory mechanism, taking place in af-
fected areas at early stages of the disease process, which cannot be
sustained as neuronal degeneration progresses (Haier et al.,
2003).
In summary, ets-2 overexpression in cultured HCN leads to
activation of a mitochondrial death apoptotic pathway. In
DS/AD brains, upregulation of ets-2 appears closely associated
with AD neurodegenerative lesions. Chronic oxidative stress in
DS and AD brains may promote ets-2 expression, which in turn
may predispose to the activation of a mitochondrial death path-
way. Thus, modulation of ets-2 expression and preservation of
redox status and mitochondrial function may be relevant to pro-
tect neuronal homeostasis and to prevent additional deteriora-
tion of cognitive ability and development of AD pathology in DS
subjects.
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